Long-term therapeutic effect of stereotactic ablative radiotherapy for pulmonary oligometastasis
10.3760/cma.j.cn113030-20200628-00323
- VernacularTitle:肺寡转移瘤立体定向消融放疗的长期疗效观察
- Author:
Xiaoli ZHENG
;
Peizan NI
;
Yanan SUN
;
Ke YE
;
Chengcheng FAN
;
Shuai SONG
;
Yang YANG
;
Nan WANG
;
Xiaohui WANG
;
Hui LUO
;
Hong GE
- From:
Chinese Journal of Radiation Oncology
2021;30(4):343-347
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of stereotactic ablative radiotherapy (SABR) in patients with pulmonary oligometastases.Methods:Clinical data of patients with pulmonary metastases treated with SABR from 2011 to 2018 were retrospectively analyzed. The local control rate (LCR) and overall survival (OS) were calculated by Kaplan- Meier method. log-rank test was used for univariate analysis and Cox’s regression model for multivariate analysis. Results:A total of 214 lung metastases were detected in 159 patients, and the median follow-up time was 43 months. The 1-, 3-and 5-year LCR were 90.1%, 73.9% and 65.8%, respectively. The 1-, 3-and 5-year OS were 73.8%, 43.6% and 11.9%, respectively. Univariate analysis showed that biological effective dose (BED)≥100 Gy was significantly correlated with LCR ( P=0.033). Cox’s multivariate analysis showed that BED and primary tumor source were the independent prognostic factors of LCR ( P=0.023, P=0.043). No>grade 3 adverse events were observed in all patients during treatment. Conclusions:SABR is a safe and effective treatment of lung oligometastases. SABR should be actively aD ministered for pulmonary oligometastases, especially for those with lesions from lung cancer and the radiation dose should be selected as BED ≥100 Gy.
